Literature DB >> 16373891

Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study.

Eric J Brunner1, Martin J Shipley, Daniel R Witte, John H Fuller, Michael G Marmot.   

Abstract

OBJECTIVE: Glucose intolerance is a risk factor for coronary disease, but there is uncertainty about the shape of the dose-response relationship between glucose level and risk of coronary mortality. We examined the prospective relation of 2-h postload blood glucose (2hBG) with coronary and other major causes of mortality over 33 years. RESEARCH DESIGN AND METHODS: A 50-g oral glucose tolerance test (OGTT) was performed at baseline (1967-1969) in 17,869 male civil servants aged 40-64 years.
RESULTS: There were 3,561 coronary deaths during 451,787 person-years of observation. All-cause, cardiovascular, and respiratory mortality were elevated among participants with glucose intolerance. The hazard of coronary mortality rose from 2hBG = 4.6 mmol/l (83 mg/dl [95% CI 4.2-5.3]). The dose-response relation was best fitted by a single slope above this level, with no evidence of nonlinearity, compared with Cox models using other threshold levels, and those containing log 2hBG terms. There was no evidence for a dose-response relationship below 2hBG = 4.6 mmol/l. Between this level and 11.1 mmol/l (200 mg/dl), the age-adjusted hazard ratio was 3.62 (95% CI 2.3-5.6). The graded relationship was attenuated by 45% after adjustment for baseline coronary heart disease (CHD), BMI, systolic blood pressure, blood cholesterol, smoking, physical activity, lung function, and employment grade.
CONCLUSIONS: A threshold model with linear slope best described the dose-response relationship between postload blood glucose and CHD mortality risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16373891     DOI: 10.2337/diacare.29.01.06.dc05-1405

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  53 in total

Review 1.  Statins and diabetes: the good, the bad, and the unknown.

Authors:  Kelly Axsom; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  Curr Atheroscler Rep       Date:  2013-02       Impact factor: 5.113

Review 2.  Prediabetes diagnosis and treatment: A review.

Authors:  Nidhi Bansal
Journal:  World J Diabetes       Date:  2015-03-15

Review 3.  Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies.

Authors:  Nancy J Brown
Journal:  J Am Soc Hypertens       Date:  2012-03-19

4.  Blood Glucose Levels of Subelite Athletes During 6 Days of Free Living.

Authors:  Felicity Thomas; Chris G Pretty; Thomas Desaive; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2016-11-01

Review 5.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.

Authors:  Rhonda M Cooper-DeHoff; Michael A Pacanowski; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

Review 6.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

Review 7.  Is it possible to reduce cardiovascular risk with glucose-lowering approaches?

Authors:  Hertzel C Gerstein
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

Review 8.  Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review.

Authors:  Nadeem Sarwar; Thor Aspelund; Gudny Eiriksdottir; Reeta Gobin; Sreenivasa Rao Kondapally Seshasai; Nita G Forouhi; Gunnar Sigurdsson; John Danesh; Vilmundur Gudnason
Journal:  PLoS Med       Date:  2010-05-25       Impact factor: 11.069

9.  Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.

Authors:  Anthony L McCall; Daniel J Cox; Robert Brodows; John Crean; Don Johns; Boris Kovatchev
Journal:  Diabetes Technol Ther       Date:  2009-06       Impact factor: 6.118

10.  Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study.

Authors:  E L M Barr; E J Boyko; P Z Zimmet; R Wolfe; A M Tonkin; J E Shaw
Journal:  Diabetologia       Date:  2009-01-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.